Nipocalimab + Vaccines: No Drama!

Big news for anyone following new antibody treatments: Nipocalimab, which could help with hemolytic disease in newborns, didn’t mess with how healthy adults responded to routine vaccines in a phase 1 trial. People still got strong immune responses, even though their IgG levels dropped for a bit. Side effects were mostly mild (think: injection site reactions, dizziness), and no serious issues popped up. Looks like this treatment could play nice with your vaccine schedule! #ClinicalTrials #VaccineNews #Nipocalimab #MedicalResearch #HDFN #Health